| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Stacy L Haber | Q93137702 |
| P2093 | author name string | Brittany Scholes | |
| Casey J Buckway | |||
| David Romanet | |||
| Jennifer M Gonzales | |||
| Vera Benson | |||
| P2860 | cites work | Over the counter (OTC) artificial tear drops for dry eye syndrome | Q24186110 |
| The economic burden of dry eye disease in the United States: a decision tree analysis | Q34147677 | ||
| The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs | Q34165372 | ||
| Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study | Q34493904 | ||
| Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study | Q36093262 | ||
| Modulating leukocyte recruitment in inflammation | Q36845427 | ||
| Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study | Q36877000 | ||
| The molecular basis of leukocyte recruitment and its deficiencies | Q38068702 | ||
| Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older | Q38680274 | ||
| Depression and anxiety in dry eye disease: a systematic review and meta-analysis | Q38926020 | ||
| Refractive index and osmolality of human tears | Q39418748 | ||
| TFOS DEWS II Management and Therapy Report | Q39453364 | ||
| Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. | Q39730888 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study | Q42708147 | ||
| Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults | Q44243837 | ||
| Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). | Q46401944 | ||
| TFOS DEWS II Report Executive Summary. | Q46919939 | ||
| Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs | Q47268214 | ||
| Sleep deprivation reduces tear secretion and impairs the tear film | Q48106506 | ||
| Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial. | Q49261503 | ||
| A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye | Q83435570 | ||
| Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast | Q89349313 | ||
| Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease | Q90972349 | ||
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 2515841419870366 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Therapeutic Advances in Ophthalmology | Q59505510 |
| P1476 | title | Lifitegrast: a novel drug for patients with dry eye disease | |
| P478 | volume | 11 |
Search more.